By Mill Chart
Last update: Jul 25, 2025
Investors looking for growth opportunities often search for stocks that combine solid financials with positive technical patterns. One way to find these opportunities is by screening for stocks showing strong growth metrics, such as rising revenue and earnings, while also displaying technical breakout signals. This approach uses both financial health and market momentum to identify stocks likely to move higher. EXELIXIS INC (NASDAQ:EXEL) appears as a strong candidate under this strategy, with solid growth fundamentals and a promising technical setup.
EXELIXIS INC, a biotechnology company specializing in cancer treatments, performs well across key fundamental measures. Its fundamental analysis report gives the company an overall score of 8/10, with high marks in profitability (8/10), financial health (9/10), and growth (8/10). Here’s why these metrics are important for growth investors:
These fundamentals match the ideas in our growth investing introduction, where lasting profitability and expanding markets are crucial for long-term success. EXELIXIS’s focus on oncology—a sector with steady demand—further supports its growth outlook.
The technical analysis report gives EXELIXIS a high 10/10 rating, noting strong performance across short- and long-term periods. Key technical points include:
The mix of a tight trading range and strong trends makes EXELIXIS a potential breakout candidate, especially if it moves past the resistance area. This fits the goal of finding stocks where technical momentum supports fundamental strength.
Growth stocks with strong technical setups offer two key benefits:
EXELIXIS shows this balance. Its fundamentals suggest it can maintain growth, while its technicals indicate the market is starting to recognize this potential.
For investors interested in similar stocks, our Strong Growth Stocks with Good Technical Setup Ratings screen offers a list of stocks meeting these criteria.
Disclaimer: This analysis is not investment advice. Always do your own research or consult a financial advisor before making investment decisions.
38.63
-0.08 (-0.21%)
Find more stocks in the Stock Screener